BeiGene News - BGNE

Company Name	Stock Ticker Symbol	Market	Type
BeiGene Ltd	BGNE	NASDAQ	Depository Receipt

	Price Change	Change Percent	Stock Price	Last Traded
	5.02	3.38%	153.58	20:00:00

Open Price	Low Price	High Price	Close Price	Prev Close
152.11	150.726	154.47	153.58	148.56

more quote information »

Recent News

Date	Time	Source	Heading
4/26/2024	10:34	BW	BeiGene Demonstrates Global Progress in 2023 Responsible..
4/25/2024	07:11	BW	Globaler Onkologie-Innovator BeiGene präsentiert auf der..
4/25/2024	07:10	BW	BeiGene, innovateur mondial en oncologie, présente de..
4/24/2024	16:01	BW	Global Oncology Innovator BeiGene Highlights New Data across..
4/23/2024	19:31	BW	BeiGene erhält von der EU-Kommission die Zulassung für..
4/23/2024	06:00	BW	BeiGene Receives European Commission Approval for..
3/16/2024	11:18	BW	BeiGene、化学療法後の進行性または転移性食道扁平上皮癌の治療のためのTEVIMBRA®のFDA承認取得
3/15/2024	17:13	BW	百濟神州喜獲FDA批准，TEVIMBRA®將用於晚期或轉移性食管鱗狀細胞癌在化療後的治療
3/15/2024	16:02	BW	BeiGene reçoit l'approbation de la FDA pour TEVIMBRA® dans..
3/15/2024	02:06	BW	BeiGene erhält FDA-Zulassung für TEVIMBRA ® zur Behandlung..
3/14/2024	16:28	BW	BeiGene Receives FDA Approval for TEVIMBRA® for the..
3/14/2024	10:23	BW	マックス財団、ベイジーン、ベイジーン財団の協力により、低・中所得国の慢性リンパ性白血病患者にBRUKINSA®を初回投与
3/14/2024	05:31	BW	The Max Foundation、BeiGene和BeiGene..
3/13/2024	15:01	BW	Erste Dosen von BRUKINSA ® für Patienten mit chronischer..
3/13/2024	08:00	BW	First Doses of BRUKINSA® provided to Patients with Chronic..
3/07/2024	17:19	BW	BeiGene Announces FDA Accelerated Approval of BRUKINSA for..
3/06/2024	06:00	BW	BeiGene to Present Clinical and Preclinical Data from Broad..
2/29/2024	11:17	BW	ベイジーン、2023年第4・四半期および通期決算と事業に関する最新情報を発表
2/29/2024	10:00	BW	BeiGene Announces New Efficacy Analysis Comparing BRUKINSA®..
2/28/2024	19:56	BW	BeiGene publie ses résultats financiers du quatrième..
2/28/2024	13:13	BW	BeiGene meldet Finanzergebnisse für das vierte Quartal und..
2/28/2024	08:05	BW	BeiGene to Present at Upcoming Investor Conferences
2/28/2024	07:43	BW	ベイジーン、非小細胞肺がん治療薬チスレリズマブに対してCHMPから肯定的意見を受領
2/28/2024	06:48	BW	BeiGene公布2023年第四季及全年財務業績和最新業務情況
2/27/2024	07:24	BW	百濟神州（BeiGene）獲得 CHMP 對替雷利珠單抗（Tislelizumab）治療非小細胞肺癌的積極意見
2/27/2024	07:22	BW	BeiGene erhält positives CHMP-Gutachten für Tislelizumab zur..
2/27/2024	06:00	BW	BeiGene’s Biologics License Application for TEVIMBRA®..
2/26/2024	06:02	EDGAR2	Form 8-K - Current report
2/26/2024	06:00	BW	BeiGene Reports Fourth Quarter and Full Year 2023 Financial..
2/26/2024	05:00	BW	BeiGene Receives Positive CHMP Opinion for Tislelizumab as..
2/07/2024	06:47	PRNCA	Santé Canada approuve BRUKINSA® (zanubrutinib) dans le..
1/31/2024	06:47	PRNCA	Adults living with chronic lymphocytic leukemia (CLL) in..
1/24/2024	14:03	BW	ベイジーン、取締役会に経験豊富なライフサイエンス界のエグゼクティブ、オリビエ・ブランディクールを迎える
1/23/2024	12:04	BW	BeiGene accueille au sein de son conseil d'administration,..
1/23/2024	11:55	BW	BeiGene heißt den erfahrenen Life Sciences Manager Olivier..
1/23/2024	06:03	EDGAR2	Form 8-K - Current report
1/23/2024	06:00	BW	BeiGene Welcomes Experienced Life Sciences Executive Olivier..
12/22/2023	06:00	BW	FDA Approves Label Update for BRUKINSA® (zanubrutinib) in..
12/21/2023	06:01	BW	BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare..
11/29/2023	16:01	BW	BeiGene to Host ASH Investor Meeting in Person and via..
11/28/2023	06:00	BW	BeiGene to Present New Data Highlighting Hematology..
11/21/2023	06:00	BW	BeiGene and Ensem Therapeutics Announce Partnership to..
11/17/2023	06:00	BW	BeiGene Receives European Commission Approval for BRUKINSA®..
11/09/2023	16:08	EDGAR2	Form 8-K - Current report
11/09/2023	16:01	BW	BeiGene Continues Global Growth with Third Quarter 2023..
11/08/2023	06:00	BW	BeiGene to Present at the Jefferies London Healthcare..
10/20/2023	16:04	EDGAR2	Form 8-K - Current report
10/20/2023	06:00	BW	BRUKINSA® Receives Positive Recommendation from NICE in U.K...
10/17/2023	16:01	BW	BeiGene Announces the Phase 3 RATIONALE 315 Trial Met..
10/16/2023	06:00	BW	BeiGene Presentations at ESMO 2023 Demonstrate Robust..